ClinicalTrials.gg
RecruitingNCT06235918Updated Feb 1, 2024

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of Tislelizumab and Nab-paclitaxel in Head and Neck Squamous Cell Carcinomas and Resectable Head and Neck Squamous-cell Carcinoma, sponsored by Xiang Lu. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Xiang Lu · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Jan 2023, registered Jan 2024).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck — 8 open to participants now, 13 under way, none of them phase 3. tislelizumab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
10th of 16
30 · median 41
Started
2023
with 4 others
Phase 2
12 of 16
7 open now
Primary completion
2025-01
later than 2 of 12 live
Registered
10th of 16
by date

Among the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 10th largest by planned enrollment, is one of 5 that started in 2023, is one of 12 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 10th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

8 of the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy. The purpose of this study is to evaluate the safety and efficacy of neoadjuvant of tislelizumab combined with platinum doublet for resectable locally-advanced head and neck squamous-cell carcinoma .

03

Conditions studied

  • Head and Neck Squamous Cell Carcinomas
  • Resectable Head and Neck Squamous-cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who voluntarily participate in the project and sign the .
  2. Be 18 years of age on day of signing informed consent.
  3. The performance status of the (ECOG) is 0-1.
  4. According to the 8th edition of the guidelines of the American Joint Committee on Cancer (AJCC), patients with stage III-IVA tumors confirmed by pathology as head and neck squamous cell carcinoma.
  5. Resectable tumors were evaluated by head and neck surgeons before enrollment to exclude clinical evidence of distant .
  6. Demonstrate adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. The patient has abnormal blood indicators, abnormal liver and kidney function.
  2. The patient has received prior systemic anti-cancer therapy for head and neck squamous cell carcinoma including agents within 3 months of first dose of study treatment.
  3. The patient has previously suffered from other tumors , or has previously undergone anti-tumor treatments such as surgery, chemotherapy, and radiotherapy within the past 5 years.
  4. The entire clinical research process cannot be completed due to personal, social and economic reasons.
  5. Serious systemic diseases in the past and the diseases cannot be cured or controlled by drugs .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant therapy of tislelizumab with chemotherapy

    Neoadjuvant Tislelizumab plus double platinum based chemotherapy for 2 cycles

    Drug: Tislelizumab · Drug: Nab-paclitaxel · Drug: Carboplatin

Interventions

  • Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles

    Also known as: BGB-A317

  • DrugAlbumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles

  • AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (PCR)

    Time frame: From neoadjuvant therapy to surgical resection, up to 6 weeks

Secondary outcomes

  1. Major Pathological Response (MPR)

    In the pathological examination of resected specimens, the proportion of residual tumor cells was less than 10%.

    Time frame: From neoadjuvant therapy to surgical resection, up to 6 weeks

  2. 3-year Disease-free survival (DFS) rate

    Time from randomization to disease recurrence or death of any cause

    Time frame: 3-years after surgery

  3. 3-year overall survival(OS)rate

    The proportion of all study cases in which no death from any cause occurred within 3 years after surgery

    Time frame: 3-years after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2025, 24 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 24 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Feb 1, 2024
StartActual
Jan 1, 2023
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2026
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06235918
Lead sponsor
Xiang Lu
Responsible party
Xiang Lu (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Feb 1, 2024
Start date
Jan 1, 2023
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Feb 1, 2024

Study contacts

Xiang Lu, professor
Contact
luxiangent@hotmail.com
027-83662691
Guangyuan Hu, professor
principal investigator · Tongji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion